Lineage Cell Therapeutics, Inc. Recognition of Deferred Revenue
Lineage Cell Therapeutics, Inc. (LCTX) reported Recognition of Deferred Revenue of $308.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-16.
Discontinued › Income Statement › Other Income
us-gaap:RecognitionOfDeferredRevenue · last filed 2017-03-16
- Lineage Cell Therapeutics, Inc. recognition of deferred revenue for the quarter ending 2014-03-31 was -$57.40K.
- Lineage Cell Therapeutics, Inc. recognition of deferred revenue for the quarter ending 2013-03-31 was $0.00.
- Lineage Cell Therapeutics, Inc. recognition of deferred revenue for fiscal 2016 was $308.00K.
- Lineage Cell Therapeutics, Inc. recognition of deferred revenue for fiscal 2015 was -$102.00K, a 10300.00% decline from fiscal 2014.
- Lineage Cell Therapeutics, Inc. recognition of deferred revenue for fiscal 2014 was $1.00K.
| Period end | Recognition of Deferred Revenue 3 month | Recognition of Deferred Revenue 12 month |
|---|---|---|
| 2016-12-31 | $308.00K 10-K · filed 2017-03-16 | |
| 2015-12-31 | -$102.00K 10-K · filed 2017-03-16 | |
| 2014-12-31 | $1.00K 10-K · filed 2017-03-16 | |
| 2014-03-31 | -$57.40K 10-Q · filed 2014-05-12 | |
| 2013-03-31 | $0.00 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |